Company: InflaRx N.V.
Job title: Immunoderm Program Director
Vilobelimab, a First-In-Class Anti-C5a Antibody for the Treatment of the Neutrophil Driven Skin Diseases Hidradenitis Suppurativa & Pyoderma Gangraenosum 2:50 pm
Revisiting the role of C5a in neutrophil driven skin diseases Connecting the dots – vilobelimab development for neutrophil driven skin diseases A view on endpoints for HS – whatmatters for patients?Read more
day: Day Two